MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    The Corticobasal Degeneration Functional Rating Scale (CBD-FS)

    A. Lang, G. Stebbins, A. Boxer (Toronto, Canada)

    Objective: To develop a patient/care giver-reported scale that is capable of assessing functional disability in CBD that can be easily and reliably used in clinical…
  • 2017 International Congress

    Apathy in adolescents with Tourette syndrome (TS), more than a teenager attitude

    W. Deeb, M. Hensley, A. Bernier, I. Malaty (Gainesville, FL, USA)

    Objective: To explore the presence of apathy in teenagers with TS. Background: TS is a complex neuropsychiatric disorder generally classified as a hyperkinetic disorder. Apathy…
  • 2017 International Congress

    A Phase 2, Open-Label, Dose-Escalating Study to Evaluate the Safety and Preliminary Efficacy of Daxibotulinumtoxina for Injection (RT002) in Isolated Cervical Dystonia

    C. Comella, J. Jankovic, D. Truong, A. Brashear, A. Patel, M. Evatt, C. Chung, R. Rubio (Chicago, IL, USA)

    Objective: To report preliminary 24-week outcomes of an open-label trial of daxibotulinumtoxinA for injection (RT002) for the treatment of isolated cervical dystonia (CD). (ClinicalTrials.gov ID: NCT02706795) Background:…
  • 2017 International Congress

    Cost-utility analysis of flexible interval incobotulinumtoxinA versus onabotulinumtoxinA in the management of blepharospasm and cervical dystonia in Ontario, Canada.

    M.-E. Gendron, M.-E. Gendron, R. Kazerooni (Burlington, ON, Canada)

    Objective: To carry out a cost-utility analysis for IncoBTX administered with flexible treatment intervals compared to OnaBTX in the management of BL and CD from…
  • 2017 International Congress

    Clinical effects are persistent at the end of one abobotulinumtoxinA injection cycle in cervical dystonia – results from a meta-analysis of 1091 subjects

    R. Trosch, V. Misra, P. Maisonobe, S. Om (Farmington Hills, MI, USA)

    Objective: Evaluate the impact of one injection cycle of abobotulinumtoxinA (AboBoNT-A; Dysport®) on the clinical characteristics of cervical dystonia (CD). Background: The pharmacologic effects of…
  • 2017 International Congress

    Oromandibular dystonia (OMD): A Prospective, Single-Blind Trial of AbobotulinumtoxinA (AboA)

    S. Factor, M. Silver, J. Hanfelt, E. Sperine, L. Scorr, A. Freeman, H. Jinnah (Atlanta, GA, USA)

    Objective: To examine the safety and efficacy of AboA in OMD Background: OMD causes involuntary movements of the lower facial, masticatory, and lingual muscles.  The…
  • 2017 International Congress

    Sensory trick in a dystonic patient: insights from Magnetoencephalogram

    A. Mahajan, A. Zillgitt, S. Bowyer, C. Sidiropoulos (Detroit, MI, USA)

    Objective: To explore the mechanism of action of a sensory trick by comparing cerebral oscillations at network level, with a sensory trick and administration of…
  • 2017 International Congress

    Physical Activity in Early Parkinson Disease

    S. Mantri, M. Fullard, J. Duda, J. Morley (Philadelphia, PA, USA)

    Objective: To characterize physical activity habits in patients with early Parkinson disease (PD). Background: Physical activity is an important therapy for PD as it may…
  • 2017 International Congress

    Oscillatory Activity in the Nucleus Basalis of Meynert

    M. Nazmuddin, D. Oterdoom, J. van Zijl, A. Kampman, J. van Dijk, G. Drost, T. van Laar, M. Beudel (Groningen, Netherlands)

    Objective: Characterize oscillatory activity in and around the nucleus basalis of Meynert (NBM). Background: The NBM is the major source of cholinergic innervation to the…
  • 2017 International Congress

    Development of a Clinical Outcomes Assessment (COA) in Pantothenate-Kinase Associated Neurodegeneration (PKAN): Item Generation and Clinimetric Properties

    R. Marshall, A. Collins, M. Escolar, H.A. Jinnah, T. Klopstock, M. Kruer, A. Videnovic, A. Robichaux-Viehoever, L. Swett, D. Revicki, R. Bender, W. Lenderking (Cambridge, MA, USA)

    Objective: To develop a clinical outcome assessment (COA) scale that measures key aspects of functioning and daily living in patients with pantothenate kinase-associated neurodegeneration (PKAN)…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 155
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley